Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Natera (NTRA) and Incyte (INCY) are collaborating on a phase II colorectal cancer study. The trial will use Natera's Signatera test to guide treatment with Incyte's investigational immunotherapy INCA33890. Patients testing positive for minimal residual disease (MRD) post-treatment may be eligible. Natera will provide trial matching services.
How this was made
The 30-second read
Why it matters
The partnership creates a new data source for both companies, potentially expanding market adoption of MRD testing and advancing Incyte's immunotherapy pipeline.
Market read
First‑time disclosure of a Phase II collaboration in colorectal cancer, likely to generate short‑term interest in both stocks and broader liquid‑biopsy sector.
What to watch
The collaboration's financial terms are undisclosed; potential cash outlay or revenue sharing could affect near‑term earnings.
Background
The announcement was released via a Business Wire press release on November 10, 2026, highlighting Natera's Signatera MRD test and Incyte's bispecific immunotherapy candidate.
Ticker impact
Natera announced a new clinical collaboration with Incyte for a Phase II colorectal cancer study, the first public disclosure of this partnership.
potential upside as investors price in future trial data and partnership revenue
First‑time announcement of a biotech partnership typically lifts the stock on expectations of future earnings and data milestones.
Incyte entered a clinical collaboration with Natera to test its bispecific immunotherapy INCA33890 in a Phase II colorectal cancer trial, newly disclosed.
potential modest upside as the market values the added trial data and partnership
New trial collaborations are viewed favorably for pipeline diversification and future commercial potential.
Market effects
Strengthens the broader liquid biopsy and precision oncology sector by adding a high‑profile trial partnership.
May lift US biotech sentiment, especially for companies focused on MRD‑guided therapies.
Adds to global interest in colorectal cancer treatments and could influence international biotech funding trends.
Counterpoint
If the trial fails to meet endpoints, the partnership could become a liability, pressuring both stocks.
Key entities
- CompanyNatera, Inc.
US‑listed provider of cell‑free DNA diagnostics, ticker NTRA.
- CompanyIncyte Corporation
US‑listed biopharma focused on oncology, ticker INCY.
